← ANALYST RATINGS · TIPRANKS
Allogene Therapeutics (ALLO): analyst forecast and price target
Analyst consensus
Strong Buy6 Buy1 Hold0 Sell
Ratings of 7 analysts in the last 3 months12-month forecast
Based on 7 price targets given in the last 3 months, the average target is $10.25, the highest $14.00, the lowest $8.00. The average is +682.4% from the last price of $1.31.
Analyst ratings 15
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $1.50 → $1.00−33.3% | Sell | −23.7% | Downgrade | 14.10.26on TipRanks 10:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $1.50 → $1.00−33.3% | Hold | −23.7% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $1.50 | Hold | +14.5% | Reiterated | 30.09.26on TipRanks 16:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $1.50 | Hold | +14.5% | Reiterated | 30.09.26on TipRanks 16:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $1.50 | Hold | +14.5% | Reiterated | 30.09.26on TipRanks 16:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $1.50 | Hold | +14.5% | Reiterated | 30.09.26on TipRanks 16:05 | — | |
| John Newman★★★★★★★★★★#3035 · hits 44% · avg +4.1% | Canaccord Genuity | $14.00 | Buy | +968.7% | Reiterated | 30.09.26on TipRanks 09:06 | −1.0%next day −3.9% · 5 days −12.5% | ↗ |
| Brian Cheng★★★★★★★★★★#1122 · hits 55% · avg +14.0% | J.P. Morgan | — | Hold | — | Reiterated | 17.08.26on TipRanks 07:53 | +1.9%next day −1.7% · 5 days −1.2% | ↗ |
| Unknown Analyst | UBS | $8.00 | Buy | +510.7% | Assigned | 13.08.26on TipRanks 10:35 | −5.0%next day +3.7% · 5 days +8.0% | ↗ |
| Biren Amin★★★★★★★★★★#1671 · hits 46% · avg +7.6% | Piper Sandler | $10.00 | Buy | +663.4% | Reiterated | 13.08.26on TipRanks 07:10 | −5.0%next day +3.7% · 5 days +8.0% | ↗ |
| Sami Corwin★★★★★★★★★★#511 · hits 55% · avg +18.5% | William Blair | — | Buy | — | Reiterated | 13.08.26on TipRanks 04:55 | −5.0%next day +3.7% · 5 days +8.0% | ↗ |
| Tyler Van Buren★★★★★★★★★★#42 · hits 64% · avg +38.8% | TD Cowen | — | Buy | — | Reiterated | 12.08.26on TipRanks Aug 13 10:35 | −2.6%next day −5.0% · 5 days +8.2% | ↗ |
| Luca Issi★★★★★★★★★★#11187 · hits 39% · avg −2.1% | RBC Capital | $9.00 | Buy | +587.0% | Reiterated | 12.08.26on TipRanks Aug 13 07:45 | −2.6%next day −5.0% · 5 days +8.2% | ↗ |
| Matthew Biegler★★★★★★★★★★#3953 · hits 39% · avg +3.4% | Oppenheimer | $7.00 | Buy | +434.4% | Reiterated | 14.05.26on TipRanks 09:30 | −8.9%next day −5.3% · 5 days −7.7% | ↗ |
| Robert Burns★★★★★★★★★★#272 · hits 52% · avg +25.9% | H.C. Wainwright | $12.00 → $11.00−8.3% | Buy | +739.7% | Reiterated | 16.04.26on TipRanks Apr 14 06:20 | −26.7%next day −5.6% · 5 days +0.4% | ↗ |
| Roger Song★★★★★★★★★★#4779 · hits 41% · avg +2.6% | Jefferies | $6.00 → $10.00+66.7% | Buy | +663.4% | Reiterated | 15.04.26on TipRanks 12:16 | −5.6%next day +9.0% · 5 days +8.5% | ↗ |
| Jack Allen★★★★★★★★★★#12322 · hits 30% · avg −16.3% | Robert W. Baird | $7.00 → $9.00+28.6% | Buy | +587.0% | Reiterated | 14.04.26on TipRanks 07:35 | −26.7%next day −5.6% · 5 days +0.4% | ↗ |
| William Pickering★★★★★★★★★★#5908 · hits 58% · avg +1.8% | Bernstein | $1.60 → $3.85+140.6% | Hold | +193.9% | Reiterated | 14.04.26on TipRanks 07:30 | −26.7%next day −5.6% · 5 days +0.4% | ↗ |
| Reni Benjamin★★★★★★★★★★#12340 · hits 34% · avg −9.2% | Citizens JMP | $5.00 → $8.00+60.0% | Buy | +510.7% | Reiterated | 14.04.26on TipRanks 05:55 | −26.7%next day −5.6% · 5 days +0.4% | ↗ |
| Samantha Semenkow★★★★★★★★★★#6889 · hits 47% · avg +0.7% | Citi | $4.00 | Buy | +205.3% | Assigned | 09.04.26on TipRanks Apr 13 06:30 | +7.2%next day −6.5% · 5 days −21.8% | ↗ |
| Asthika Goonewardene★★★★★★★★★★#5130 · hits 41% · avg +2.0% | Truist Financial | $10.00 | Buy | +663.4% | Reiterated | 13.03.26on TipRanks 07:45 | −2.3%next day +0.7% · 5 days −11.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Allogene Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $10.25 at a price of $1.60 (+540.6%); now: $10.25 at $1.31 (+682.4%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 17 | 11 | 5 | 4 | 5 | 5 |
| Buy | 8 | 5 | 4 | 5 | 5 | 3 |
| Hold | 2 | 2 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.15 (from $-0.18 to $-0.11). Last quarter: $-0.13.
Best top-analyst consensus in the sector · Healthcare
About Allogene Therapeutics
- CEO: Zachary Roberts
- Employees: 151
- 210 East Grand Avenue, South San Francisco, CA, 94080, US
- www.allogene.com
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prepared for market release to address relapsed/refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL) in both children and adults. The company's portfolio also encompasses ALLO-501, an anti-CD19 allogeneic CAR T-cell candidate currently in Phase I clinical trials for R/R non-Hodgkin lymphoma. A related therapeutic, ALLO-501A, is progressing through Phase I/II studies, targeting R/R large B-cell lymphoma or transformed follicular lymphoma. Furthermore, Allogene is advancing several other promising candidates: ALLO-715, an allogeneic CAR T-cell therapy in Phase I for R/R multiple myeloma; ALLO-605, another allogeneic CAR T-cell designed for multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody. Their investigational therapies also include those targeting CD70 for renal cell cancer, ALLO-819 (an allogeneic CAR T-cell treatment) for acute myeloid leukemia, and DLL3 for small cell lung cancer and other aggressive neuroendocrine tumors. Allogene maintains a robust network of strategic alliances, which includes licensing and collaboration agreements with organizations such as Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. They also hold a clinical trial collaboration with SpringWorks Therapeutics, Inc. Additionally, a strategic partnership with The University of Texas MD Anderson Cancer Center supports the preclinical and clinical evaluation of their allogeneic CAR T-cell product pipeline. Founded in 2017, the company's corporate headquarters are located in South San Francisco, California.
Data from the stock’s TipRanks forecast page, read 92 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗